Next Article in Journal
In Vitro Systematic Drug Testing Reveals Carboplatin, Paclitaxel, and Alpelisib as a Potential Novel Combination Treatment for Adult Granulosa Cell Tumors
Next Article in Special Issue
Radiomics Features of 18F-Fluorodeoxyglucose Positron-Emission Tomography as a Novel Prognostic Signature in Colorectal Cancer
Previous Article in Journal
Neuroendocrine Neoplasms: Identification of Novel Metabolic Circuits of Potential Diagnostic Utility
Previous Article in Special Issue
Prognostic Inflammatory Index Based on Preoperative Peripheral Blood for Predicting the Prognosis of Colorectal Cancer Patients
Article

Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma

1
Division of Oncology, Department of Medicine, Huntsman Cancer Institute, 2000 Circle of Hope Dr., Salt Lake City, UT 84112, USA
2
Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
3
Eurobiodev, 2040 Avenue du Père Soulas, 34000 Montpellier, France
4
Centre Hospitalier Princesse Grace, 1 Avenue Pasteur, Principauté de Monaco, 98000 Monaco, Monaco
5
Laboratoire de Biochimie et Biologie Moleculaire, CITOHL, Centre Hospitalier Lyon-Sud, 69310 Pierre-Bénite, France
6
ECS-Progastrin, Chemin de la Meunière 12, 1008 Prilly, Switzerland
*
Authors to whom correspondence should be addressed.
Cancers 2021, 13(3), 375; https://doi.org/10.3390/cancers13030375
Received: 23 November 2020 / Revised: 13 January 2021 / Accepted: 15 January 2021 / Published: 20 January 2021
(This article belongs to the Collection Cancer Biomarkers)
Metastatic renal cell carcinoma (mRCC) accounts for one-third of all newly diagnosed renal cell cancers. A better understanding of the biology and molecular basis of disease progression has resulted in several drug targets being identified and led to approval of several new drugs for treating mRCC in the past decade. A growing need has emerged for identifying novel molecular tumor biology based and stage-specific prognostic and predictive biomarkers in mRCC reflective of biology beyond the currently available prognostic models which are solely based on clinical characteristics. We investigated hPG80 (circulating progastrin), which is associated with kidney cancer biology and found that hPG80 levels is both an independent prognostic marker in mRCC and also improves current clinical prognostic models. This will help stratify mRCC patients more accurately in future and improve the management of mRCC patients.
Precise management of kidney cancer requires the identification of prognostic factors. hPG80 (circulating progastrin) is a tumor promoting peptide present in the blood of patients with various cancers, including renal cell carcinoma (RCC). In this study, we evaluated the prognostic value of plasma hPG80 in 143 prospectively collected patients with metastatic RCC (mRCC). The prognostic impact of hPG80 levels on overall survival (OS) in mRCC patients after controlling for hPG80 levels in non-cancer age matched controls was determined and compared to the International Metastatic Database Consortium (IMDC) risk model (good, intermediate, poor). ROC curves were used to evaluate the diagnostic accuracy of hPG80 using the area under the curve (AUC). Our results showed that plasma hPG80 was detected in 94% of mRCC patients. hPG80 levels displayed high predictive accuracy with an AUC of 0.93 and 0.84 when compared to 18–25 year old controls and 50–80 year old controls, respectively. mRCC patients with high hPG80 levels (>4.5 pM) had significantly lower OS compared to patients with low hPG80 levels (<4.5 pM) (12 versus 31.2 months, respectively; p = 0.0031). Adding hPG80 levels (score of 1 for patients having hPG80 levels > 4.5 pM) to the six variables of the IMDC risk model showed a greater and significant difference in OS between the newly defined good-, intermediate- and poor-risk groups (p = 0.0003 compared to p = 0.0076). Finally, when patients with IMDC intermediate-risk group were further divided into two groups based on hPG80 levels within these subgroups, increased OS were observed in patients with low hPG80 levels (<4.5 pM). In conclusion, our data suggest that hPG80 could be used for prognosticating survival in mRCC alone or integrated to the IMDC score (by adding a variable to the IMDC score or by substratifying the IMDC risk groups), be a prognostic biomarker in mRCC patients. View Full-Text
Keywords: metastatic renal cell carcinoma (mRCC); hPG80; IMDC; blood-based prognostic biomarker; circulating progastrin metastatic renal cell carcinoma (mRCC); hPG80; IMDC; blood-based prognostic biomarker; circulating progastrin
Show Figures

Figure 1

MDPI and ACS Style

Kohli, M.; Tan, W.; Vire, B.; Liaud, P.; Blairvacq, M.; Berthier, F.; Rouison, D.; Garnier, G.; Payen, L.; Cousin, T.; Joubert, D.; Prieur, A. Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma. Cancers 2021, 13, 375. https://doi.org/10.3390/cancers13030375

AMA Style

Kohli M, Tan W, Vire B, Liaud P, Blairvacq M, Berthier F, Rouison D, Garnier G, Payen L, Cousin T, Joubert D, Prieur A. Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma. Cancers. 2021; 13(3):375. https://doi.org/10.3390/cancers13030375

Chicago/Turabian Style

Kohli, Manish, Winston Tan, Bérengère Vire, Pierre Liaud, Mélina Blairvacq, Frederic Berthier, Daniel Rouison, George Garnier, Léa Payen, Thierry Cousin, Dominique Joubert, and Alexandre Prieur. 2021. "Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma" Cancers 13, no. 3: 375. https://doi.org/10.3390/cancers13030375

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop